Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH hydroxyurea study in African children with sickle cell anemia
PACTR202105884908295Phase 2Unknown
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of hydroxyurea in sickle cell anemia (SCA) (2 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Percentage of participants with dose-limiting toxic events. Status: unknown.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on PACTR202105884908295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202105884908295.